Abstracts tagged "Osteoarthritis"

Abstract Number: 1808 • ACR Convergence 2023
Tobacco Smoking Reduces the Incidence and Delays the Progression of Knee Osteoarthritis: 10-year Retrospective Cohort Study Based on Korea National Health Insurance Service-Health Screening Database
Junyong Park¹, Minkook Son², Sang Yeob Lee¹, Wontae Chung¹ and SungWon Lee¹, ¹Dong-A University Hospital, Busan, South Korea, ²Dong-A University, Busan, South Korea
Background/Purpose: There are conflicting results about relationship between smoking and incidence of knee osteoarthritis (OA). The effect of smoking to preexisting knee OA has also…
Abstract Number: 1983 • ACR Convergence 2023
Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial
Cecilie Bartholdy¹, Anna Døssing², Zara Stisen¹, Sabrina Mai Nielsen³, Henning Bliddal¹, Robin Christensen⁴, Marius Henriksen¹ and Karen Ellegaard¹, ¹The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ²The Parker Institutte, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ³The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark
Background/Purpose: Hand Osteoarthritis (OA) is common and causes pain and disability. Heat is anecdotally known to moderate symptoms and is conditionally recommended as a treatment…
Abstract Number: 2468 • ACR Convergence 2023
Association Between Gut Microbiome-related Metabolites and Symptomatic Hand Osteoarthritis in Two Independent Cohorts
Jie Wei¹, Zidan Yang², Jiatian Li³, Yuqing Zhang⁴, Weiya Zhang⁵, Michael Doherty⁵, Tuo Yang⁶, Yuanheng Yang³, Hui Li³, Yilun Wang³, Ziying Wu³, Changjun Li⁷, Guanghua Lei³ and Chao Zeng³, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ³Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Academic Rheumatology, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham, United Kingdom, ⁶Department of Health Management Center, Xiangya Hospital, Central South University, Changsha, China, ⁷National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Since gut microbiome dysbiosis can cause inflammatory disorders by affecting host metabolism, we postulate that the gut microbiome and related metabolites could play a…
Abstract Number: 0313 • ACR Convergence 2023
The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis
Diana, Xin Hui Chan¹, Seyed Ehsan Saffari², Steven, Bak Siew Wong³, Seng Jin Yeo¹, Vikki Wylde⁴, Julian Thumboo¹ and Ying Ying Leung¹, ¹Singapore General Hospital, Singapore, Singapore, ²Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, ³Sengkang General Hospital, Singapore, Singapore, ⁴University of Bristol, Bristol, United Kingdom
Background/Purpose: To evaluate the association between pre-operative pain catastrophizing and pain and function outcomes up to one year after knee arthroplasty. Methods: We used data…
Abstract Number: 0818 • ACR Convergence 2023
Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial
Eric Grigsby¹, Stephen D. Collins², Leonard Kapural³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Neurovations Clinical Research, Napa, CA, ²Xalud Therapeutics, Inc., Chicago, IL, ³Center for Clinical Research, Winston-Salem, NC, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: Interleukin (IL)-10 is a regulator of cytokine activity and has the potential to restore homeostasis in osteoarthritis (OA) of the knee. Unfortunately, relatively short…
Abstract Number: 0871 • ACR Convergence 2023
Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease
Fernando Figueroa¹, Angela Court², Patricia Luz Crawford², Ana Maria Vega Letter², Francesca Velarde², Cynthia Garcia² and Maroun Khoury², ¹IMPACT, Santiago de Chile, Chile, ²IMPACT, Santiago, Chile
Background/Purpose: Osteoarthrosis (OA) is a leading cause of pain, disability and early mortality, with no disease modifying treatments. Mitochondrial dysfunction is a known driver of…
Abstract Number: 1039 • ACR Convergence 2023
Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study
Katherine Yates¹, Carolina Alvarez², Todd Schwartz³, Serena Savage-Guin⁴, Jordan Renner⁴, Catherine Bakewell⁵, Minna Kohler⁶, Janice Lin⁷, Jonathan Samuels⁸ and Amanda Nelson⁴, ¹University of North Carolina Medical Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Stanford University, Palo Alto, CA, ⁸NYU Langone, Rye Brook, NY
Background/Purpose: Ultrasound (US) allows for visualization of many features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and articular cartilage damage. Additionally, US is…
Abstract Number: 1197 • ACR Convergence 2023
Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial
Schnitzer Thomas¹, Helene Rovsing², Edith Lau³, Sidsel Boll⁴, Ballari Brahmachari⁵, Richard Chou⁶, Tarini Joshi⁵, Roni Wechsler⁷, Siu-Long Yao⁵, Sveta Weiner⁵, Asger Bihlet⁸ and Philip Conaghan⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Sanos Clinic, Gandrup, Denmark, ³Hong Kong Center for Clinical Research, Hong Kong, China, ⁴Sanos Clinic, Vejle, Denmark, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, ⁷Moebius Medical, Tel Aviv, Israel, ⁸NBCD, Soeborg, Denmark, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Safe and effective therapies are needed for OA pain. MM-II, a novel suspension of large, empty, multilamellar liposomes composed of dimyristoylphosphatidylcholine and dipalmitoylphosphatidylcholine, effectively…
Abstract Number: 1820 • ACR Convergence 2023
Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study
Dhruvkumar Gadhiya¹, Utsav Patel², Hiren Chhayani³, Krushi Shah³, Sneh Patel³, Victor Adedara⁴, Divya Patel³, Hardik Desai⁵ and Swetha Chittipolu⁶, ¹St.Luke's University Health, Anderson Campus, Easton, PA, ²Tulane University, New Orleans, LA, ³G.M.E.R.S. Medical College, Gandhinagar, Gandhinagar, India, ⁴St George’s University SOM, True Blue Greneda, True Blue, Grenada, ⁵Gujarat Adani Institute of Medical Sciences, Bhuj, India., Bhuj, India, ⁶North Mississippi Medical Center, Tupelo, MS
Background/Purpose: Osteoarthritis (OA) is a prevalent and debilitating musculoskeletal condition that has imposed a significant burden on the United States (US) healthcare system. This study…
Abstract Number: 1984 • ACR Convergence 2023
Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis
Mukesh Ahuja¹, Donna Skerrett², Curtis Gravance³, Divya Navuru⁴, Ravi Krishnan⁵, Charles Inderjeeth⁶, Philip Bloom⁷ and Schnitzer Thomas⁸, ¹Paradigm Biopharmaceuticals, Oak Brook, IL, ²Paradigm Biopharmaceuticals, New York, NY, ³Paradigm Biopharmaceuticals, Melba, ID, ⁴Paradigm Biopharmaceuticals, Melbourne, Australia, ⁵Paradigm Biopharmaceuticals, Adelaide, Australia, ⁶University of Western Australia / Linear Clinical Research, Perth, Australia, ⁷Sportsmed Biologic, Melbourne, Australia, ⁸Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is an inflammatory joint disease, causing chronic pain, disability, and reduced quality of life. Affected joints may include the knee, hip, and…
Abstract Number: 2469 • ACR Convergence 2023
Associations Between Body Composition Measurements of Obesity and the Radiographic Progression of Hand Osteoarthritis: Data from the Dong-gu Study
Sung-Eun Choi¹, Hyemin Jeong¹, Dong-Jin Park¹, Ji-Hyoun Kang², Min-Ho Shin³ and Shin-Seok Lee¹, ¹Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Previous studies have found that obesity is a risk factor for hand osteoarthritis (OA), but most have been cross-sectional studies and thus causality is…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
Abstract Number: 0819 • ACR Convergence 2023
Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Improvement in pain reported in clinical trials for osteoarthritis (OA) is typically strongly depending on the regression-to-the-mean phenomenon. Regression to the mean has been…
Abstract Number: 0872 • ACR Convergence 2023
Synovial 5-LOX-Derived Oxylipins Define a B Cell-Enriched Synovium
Jessica Murillo-Saich¹, Roxana Coras², Felipe Julio Ramirez Garcia³, Estefania Quesada-Masachs⁴, Marta Sala Climent⁵, Katharina Eschelbach⁴, Christopher Mahony⁶, Raquel Celis⁷, Aaron Armando⁸, Oswald Quehenberger⁸, Adam Croft⁶, Arthur Kavanaugh⁹, Eric Chang⁵, Juan D Canete¹⁰, Abha Singh¹ and Monica Guma¹¹, ¹Department of Medicine, University of California San Diego, La Jolla, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Hospital Clínic, Barcelona, Spain, ⁴La Jolla Institute for Immunology, La Jolla, CA, ⁵University of California San Diego, San Diego, CA, ⁶University of Birmingham, Birmingham, United Kingdom, ⁷Arthritis Unit, Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Pharmacology, University of California San Diego, La Jolla, CA, ⁹University of California San Diego, School of Medicine, Riverside, CA, ¹⁰Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹¹San Diego VA Healthcare Service, La Jolla, CA
Background/Purpose: Oxylipins are bioactive lipids derived from polyunsaturated fatty acids (PUFAs) that modulate inflammation and may remain overexpressed in refractory synovitis. These mediators in plasma…
Abstract Number: 1047 • ACR Convergence 2023
Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints
Maria I. ("Maio") Danila¹, Giovanna Rosas², Fenglong Xie², Jeffrey R Curtis³, Kiara Aaron², Stephanie Ford² and Laura Hughes⁴, ¹University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham; East Alabama Medical Center, Birmingham, AL
Background/Purpose: Infrared thermography (IRT) is an emerging technology that has the potential to rapidly assist in identifying joint inflammation in patients with joint symptoms. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].